Friday, July 10, 2026

pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease

Otsuka Beijing Research

Otsuka Beijing Research is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis, Phenylketonuri

CN HQ
NMPA registrant Type
Company details
Clinical program

AVP-786 matching placebo, AVP-786

Phase 3 · small molecule · Agitation in Patients With Dementia of the Alzheimer's Type

AVP-786 matching placebo, AVP-786 for Agitation in Patients With Dementia of the Alzheimer's Type is a Phase 3 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Internal code 20-AVP-786-307

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Otsuka Beijing Research Institute
Phase
Phase 3
Modality
small_molecule
Indication
Agitation in Patients With Dementia of the Alzheimer's Type
Status
active
Trials
1